Aadi Bioscience, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Whitehawk Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.
WhiteHawk Therapeutics has filed definitive additional materials related to its proxy statement with the SEC.
Whitehawk Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 11, 2025, featuring director elections, executive compensation advisory vote, and auditor ratification.
DEFA14A: Aadi Bioscience to Sell FYARRO, In-License ADC Portfolio, and Secure $100 Million PIPE Financing
Aadi Bioscience is urging stockholders to vote in favor of proposals to sell FYARRO, in-license antibody drug conjugates (ADCs), and secure a $100 million private investment to transform the company and maximize shareholder value.
Aadi Bioscience appoints David Dornan as Chief Scientific Officer to advance its newly in-licensed ADC portfolio, coinciding with strategic moves including the sale of FYARRO and a private placement financing.
Aadi Bioscience is seeking stockholder approval for the sale of FYARRO to Kaken Pharmaceuticals for $100 million and a $100 million PIPE financing to support the in-licensing of an ADC portfolio.
Aadi Bioscience plans to divest its FYARRO business to Kaken Investments for $100 million in cash, pending stockholder approval, and will focus on developing ADC Programs.
DEFA14A: Aadi Bioscience to Sell FYARRO, In-License ADC Portfolio, and Secure $100 Million PIPE Financing
Aadi Bioscience is set to transform its business by selling its FYARRO product, in-licensing three ADC assets, and securing $100 million in PIPE financing to advance its precision oncology pipeline.
Aadi Bioscience announces a transformative set of transactions including in-licensing a novel ADC portfolio, selling FYARRO, and securing a $100 million PIPE financing to extend its cash runway.
AADI Bioscience, Inc. has filed definitive additional materials related to its proxy statement with the SEC.
Aadi Bioscience will hold its 2024 Annual Meeting of Stockholders virtually on June 11, 2024, to vote on director elections, executive compensation, and auditor ratification.